Two recently published articles in the New England Journal of Medicine looked at the comparative efficacy of different medications for the treatment of type 2 diabetes.
Johanna Taylor Katroscik, PharmD
At least 7 biosimilars for adalimumab (Humira–AbbVie, Inc.) are expected to hit the market in 2023.
Sonya Collins
This fall, biotech Biogen and pharmaceutical company Eisai released topline data on their new antiamyloid monoclonal antibody le-canemab.
After 5 years with no breakthroughs for patients living with amyotrophic lateral sclerosis (ALS), FDA has approved a new oral treatment called Relyvrio from Amylyx Pharmaceuticals.
Lauren Howell, PharmD
Beetroot juice is well-known in the sports community as a postworkout must and performance enhancer.
Mickie Cathers